Physician Views snap poll: Dupixent impresses in younger atopic dermatitis patients; how will prescribers use it?

On Tuesday, Sanofi and Regeneron Pharmaceuticals unveiled positive Phase III data for their blockbuster atopic dermatitis therapy Dupixent in patients aged 6 to 11 years with moderate-to-severe disease.

Dupixent was initially approved for use in adults in 2017 - where it has quickly become a standard-of-care therapy - and was subsequently authorised by the FDA in March to treat adolescent atopic dermatitis patients aged 12 to 17 years.

US dermatologists we snap-polled then were impressed with Dupixent as a new treatment option for adolescent patients and prescription data show a bump in sales to reflect uptake in this age group.

On the strength of the new data, Regeneron will file an application to broaden Dupixent's label to 6 to 11 year olds in the fourth quarter. We are snap-polling US dermatologists to gauge what impact can be expected from adoption in this age group…   

__________

Q. How would you best describe the level of unmet need for an effective treatment for moderate-to-severe atopic dermatitis in patients aged 6 to 11?

None

Low

Moderate

High

__________

Q. New data show that for children (aged 6-11) with severe atopic dermatitis (covering nearly 60% of their skin surface on average), adding Dupixent to standard-of-care topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching and health-related quality of life, compared to TCS alone. In addition, the safety data were consistent with the previously documented safety profile of Dupixent in older populations, including a numerically lower rate of skin infections compared to placebo. Results at 16 weeks included:

33% of patients who received Dupixent every four weeks (300 mg) and 30% of patients who received Dupixent every two weeks (100 mg or 200 mg, based on weight) achieved clear or almost clear skin (IGA; score of 0 or 1), compared to 11% for placebo (p<0.0001 and p=0.0004, respectively).

70% of patients who received Dupixent every four weeks and 67% of patients who received Dupixent every two weeks achieved 75% or greater skin improvement (EASI-75), compared to 27% for placebo (p<0.0001 for both).

Based on these data, what is your perception of Dupixent's efficacy profile for the treatment of patients aged 6 to 11 with moderate-to-severe atopic dermatitis?

Very negative

Negative

Neutral

Positive

Very positive

__________

Q. For the 16-week treatment period, the overall rates of adverse events were 65% for Dupixent every four weeks, 67% for Dupixent every two weeks and 73% for placebo. Adverse events that were more commonly observed with Dupixent included conjunctivitis (7% for Dupixent every four weeks, 15% for Dupixent every two weeks and 4% for placebo), nasopharyngitis (13% for Dupixent every four weeks, 7% for Dupixent every two weeks and 7% placebo) and injection site reactions (10% for Dupixent every four weeks, 11% for Dupixent every two weeks and 6% for placebo). Additional pre-specified adverse events included skin infections (6% for Dupixent every four weeks, 8% for Dupixent every two weeks and 13% for placebo) and herpes viral infections (2% for Dupixent every four weeks, 3% for Dupixent every two weeks and 5% for placebo).

Based on these data, what is your perception of Dupixent's safety profile for the treatment of patients aged 6 to 11 with moderate-to-severe atopic dermatitis?

Very negative

Negative

Neutral

Positive

Very positive

__________

Q. To what extent do you think Dupixent's route of administration (subcutaneous injection every two or four weeks as per study protocol) will act as a barrier to utilisation in patients aged 6 to 11?

Not a barrier

Somewhat of a barrier

Moderate barrier

Extreme barrier

__________

Q. Assuming it is approved and you have access, how would you plan to use Dupixent for the treatment of patients aged 6 to 11 with moderate-to-severe atopic dermatitis?

Never

Rarely

Sometimes

Often

Always

__________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.